Breakthrough CAR-T Therapy in Refractory B-Cell Lymphoma: MIOT International Chennai, India Case Study
Received: 2025-10-12
Published: 2025-06-30
Abstract
CAR-T cell therapy has emerged as a promising treatment for relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), especially in patients with limited therapeutic options. We report the case of a 60-year-old male with primary chemotherapy-refractory diffuse large B-cell lymphoma (DLBCL) and comorbidities including diabetes, hypertension, and stable coronary artery disease, treated with anti-CD19 CAR-T cell therapy (NEXCAR19) at MIOT International, Chennai. Following disease progression after seven cycles of R-CHOP chemotherapy and consolidation radiotherapy, lymphocyte apheresis was performed, yielding sufficient starting material for CAR-T cell production. The patient received fludarabine–cyclophosphamide conditioning followed by infusion of 100 mL of NEXCAR19 CAR-T cells, which was well tolerated without cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. PET-CT at day +29 demonstrated a marked metabolic response (Deauville score 4). Low-dose nivolumab maintenance therapy and IMRT- based consolidation radiotherapy to residual abdominal nodes were introduced to enhance remission durability and CAR-T sensitization. This case illustrates the feasibility, safety, and promising early efficacy of anti-CD19 CAR-T therapy in chemo-refractory DLBCL and highlights the potential benefit of integrating immunotherapy with targeted radiotherapy. Long-term follow-up will determine relapse risk and sustained response.
Keywords
List of references
-
Selleslag D. Haploidentical stem cell transplantation in adults: novel strategies and future directions. Belg J Hematol. 2012;3:74-81.
-
Kumar K, Subash C. A study to identify correlation of hematopoietic progenitor cell (XN-HPC) by Sysmex cell counters with final yield of CD34+ stem cells. Blood. 2017;130(Suppl 1):5458.
-
Subash C, Kumar K. On demand plerixafor as a rescue strategy in healthy donors to augment peripheral blood stem cell collection in haploidentical transplants. Blood. 2018;132(Suppl 1):5642.
-
Kumar K, Subash C. Experience of low dose (25 mg/kg) cyclophosphamide (Chennai protocol) as post-transplantation cyclophosphamide (PTCy) in haploidentical transplants. Blood. 2021;138(Suppl 1):4857.
-
Kumar K, Subash C. Ruxolitinib as GVHD prophylaxis in haploidentical transplantation: clinical outcomes and immune modulation insights from South India. Blood. 2022;140(Suppl 1):6398.
-
Handgretinger R. Haploidentical transplantation: the search for the best donor. Blood. 2014;124(6):827- 828.
-
Ghiso A, Raiola AM, Gualandi F, Dominietto A, et al. Donor lymphocyte infusion after haploidentical BMT with post-transplant cyclophosphamide. Bone Marrow Transplant. 2014;50(1):56-61. https://doi. org/10.1038/bmt.2014.217.
-
Ciurea SO, Champlin RE. Donor selection in T-cell replete haploidentical hematopoietic stem cell transplantation: knowns, unknowns, and controversies. Biol Blood Marrow Transplant. 2013;19(2):180- 184.
-
Schwarer AP, Bollard G, Kapuscinski M, Muirhead J, et al. Long-term follow-up of a pilot study using a chemotherapy-alone protocol for killer Ig-like receptor-ligand-mismatched haploidentical hematopoietic SCT. Bone Marrow Transplant. 2011;46(10):1331-1338.
-
Chang YJ, Huang XJ. Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers. Bone Marrow Transplant. 2014;49(7):873-879.
-
Bayraktar UD, Ciurea SO. Strategies in haploidentical stem cell transplantation in adults. Turk J Haematol. 2013;30(4):342-350.
-
Solh M. Haploidentical vs cord blood transplantation for adults with acute myelogenous leukemia. World J Stem Cells. 2014;6(4):371-379.
-
Bashey A, Solomon SR. T-cell replete haploidentical donor transplantation using post-transplant cy- clophosphamide: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplant. 2014;49(8):999-1008.
-
Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, et al. Improved early outcomes using a T-cell replete graft compared with T-cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(12):1835-1844.
About the Authors
License
This work is licensed under a Creative Commons Attribution 4.0 International License.